Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

Factors Affecting Drug Biotransformation: Biological

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gut microbiota-derived TMAVA is a modulator of acute CNS-GVHD.

The Journal of experimental medicine·2025

Same author

RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.

Cancer research·2022

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 16, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Modifying enzyme replacement therapy - A perspective.

Philipp Schaible¹

¹Faculty of Biology, University of Freiburg, Freiburg, Germany.

Journal of Cellular and Molecular Medicine

|December 25, 2022

Summary

This summary is machine-generated.

This review proposes using immune cells to produce therapeutic proteins within the body, potentially eliminating the need for frequent, expensive enzyme replacement therapies and improving patient quality of life.

Keywords:

B cell Cell engineering Protein replacement T cell

More Related Videos

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Molecular Evolution of the Tre Recombinase

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

Related Experiment Videos

Last Updated: Aug 16, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Molecular Evolution of the Tre Recombinase

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

Area of Science:

Biotechnology
Immunology
Genetic Engineering

Background:

Protein deficiencies cause diseases like hemophilia A/B and lysosomal storage disorders.
Current enzyme replacement therapies are costly, require frequent infusions, and cause adverse reactions.
These limitations significantly reduce patient quality of life.

Purpose of the Study:

To propose a novel biotechnology for sustainable, in-vivo therapeutic protein production.
To reduce reliance on traditional enzyme replacement therapies.
To enhance patient quality of life by minimizing treatment burden.

Main Methods:

Utilizing circulating immune cells as a platform for protein synthesis.
Engineering immune cells with regulatory systems for controlled protein production.
Implementing feedback mechanisms to maintain stable therapeutic protein levels.

Main Results:

A proposed system for sustained, endogenous protein production within patients.
Potential to overcome limitations of current enzyme replacement therapies.
A strategy to achieve stable therapeutic protein concentrations over time.

Conclusions:

This approach offers a sustainable alternative to enzyme replacement therapy.
In-vivo protein production by immune cells could revolutionize treatment for protein deficiency disorders.
The proposed technology promises improved patient outcomes and quality of life.